We just released exclusive question and answer (Q&A) interviews with the CEO and Head of Business Development for Accellta, a revolutionary stem cell culture company. Accellta is introducing a paradigm shift to the stem cell marketplace, announcing that it can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture using large bioreactors.
With this revolutionary technology, the company has already already secured licensing deals with major players across the stem cell products marketplace, including Thermo Fisher Scientific, STEMCELL Technologies, and Miltenyi Biotec.
Of course, Thermo Fisher Scientific also made big new this week, announcing that it will be acquiring Affymetrix in a deal worth $1.3 billion.
Also, we are releasing an exclusive Q&A interview with Dr. Yael Margolin, CEO of Gamida Cell, later this week. Gamida Cell is widely known for its NiCord® product, an ex vivo expanded cell graft that uses Gamida Cell’s proprietary NAM technology to expand cells from the umbilical cord blood. For all of our clients across the stem cell and cord blood marketplace, this will be a must-read interview!
Enjoy this week’s featured articles:
PART 1 – Exclusive Q&A Interview with Dr. Itzchak Angel, CEO of Israeli Stem Cell Company, Accellta
PART 2 – Exclusive Q&A with Eran Cohen, Head of Business Development for Accellta, a Revolutionary Stem Cell Culture Company
$1.3 Billion Buy-Out – Thermo Fisher Scientific to Acquire Affymetrix
Also, did you know that BioInformant is sponsoring the upcoming “Cell & Gene Therapy World” and “Stem Cells In Vitro” conferences on January 25-27th, in Washington, DC? (Email us at Info@BioInformant.com if you’ll be there too.)
Subscribe below to be notified when other exclusive interviews are released.